Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Viridian Therapeutics (VRDN – Research Report), retaining the price target of $34.00.
Douglas Tsao has given his Buy rating due to a combination of factors related to Viridian Therapeutics’ promising pipeline and strategic positioning in the thyroid eye disease (TED) market. The company’s lead candidate, veligrotug, is expected to capture a significant market share upon its anticipated launch in 2026, backed by compelling data from the THRIVE-1 and -2 studies. These studies demonstrated veligrotug’s superior efficacy and safety profile, particularly in chronic TED patients, where it showed a notable improvement in proptosis and diplopia.
Additionally, veligrotug’s potential for a differentiated label, including data from chronic TED patients, provides a competitive edge over existing treatments like Tepezza, which lacks specific labeling for chronic TED. The shorter treatment regimen and the convenience of veligrotug further enhance its market potential. These factors, combined with the positive response from key opinion leaders and the broader medical community, underpin Tsao’s optimistic outlook and Buy rating for Viridian Therapeutics.
Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, scPharmaceuticals, and Evolus. According to TipRanks, Tsao has an average return of 7.1% and a 35.96% success rate on recommended stocks.